Bentall Operation in a Patient With Severe Hemophilia A and Marfan Syndrome by Use of a Biologic Composite Graft.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 26897233.
- Also identified by DOI 10.1016/j.athoracsur.2015.09.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe a patient with severe hemophilia A and Marfan syndrome who underwent an elective Bentall operation. Because of the severe hemophilia, anticoagulation could not be given postoperatively; thus, a biologic Valsalva conduit graft was used. During the procedure, factor VIII was given as a bolus dose just before incision, then by continous infusion intraoperatively to maintain the factor VIII activity level between 200% and 300%. Minimal postoperative bleeding occurred. The infusion was continued postoperatively at a lower dose until all chest tubes, pacing wires, and invasive catheters were removed. The patient was discharged on postoperative day 7 without adverse events.
Medical subject headings
- Biological Products
- Blood Vessel Prosthesis
- Cardiovascular Surgical Procedures
- Elective Surgical Procedures
- Heart Valve Prosthesis
- Hemophilia A
- Marfan Syndrome